(Q44117882)

English

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GI

scientific article published on 11 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Laurence Gladieff

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

A Lortholary

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

R Largillier

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

B Weber

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

J Alexandre

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

B Slama

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

J Dauba

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

D Paraiso

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

E Pujade-Lauraine

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

GINECO group France

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

11 May 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

346-352

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR149

21 January 2018

Identifiers

10.1093/ANNONC/MDR149

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

release_dna4fnu6r5de7icqmupdsmmzzq

1 reference

https://api.fatcat.wiki/v0/release/dna4fnu6r5de7icqmupdsmmzzq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21562072%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44117882&oldid=2106760399"